Core Viewpoint - VSE Corporation has announced a definitive agreement to acquire Precision Aviation Group, which is a significant strategic move for the company [2]. Group 1: Acquisition Details - The acquisition of Precision Aviation Group is expected to enhance VSE Corporation's capabilities and market position [2]. - The announcement was made during a conference call that included key executives from VSE Corporation [2]. Group 2: Financial Expectations - VSE Corporation provided preliminary results for the fourth quarter and full year 2025 during the call, indicating a focus on future financial performance [2]. - The company is utilizing non-GAAP financial measures in its presentation, with reconciliations to GAAP measures available where applicable [3].

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved net sales of EUR 11.3 billion, reflecting a growth of 13.3% year-over-year [6][12] - For the full year 2025, total sales reached EUR 43.6 billion, representing a 9.9% growth at constant exchange rates [14] - Business EPS growth was strong at 26.7%, indicating effective operational leverage [12] - Business gross margin expanded by 1.8 percentage points to 77.5%, driven by a favorable product mix and operational efficiencies [14] Business Line Data and Key Metrics Changes - Newly launched medicines and vaccines generated EUR 5.7 billion in sales, with a growth of 34% in 2025 [4][6] - Dupixent sales reached EUR 4.2 billion in Q4 and EUR 15.7 billion for the full year, with over 30% increase in patient numbers [7][8] - Beyfortus sales grew by 9.5% to EUR 1.8 billion, driven by geographic expansion [8][9] Market Data and Key Metrics Changes - The company maintained leadership in influenza and RSV vaccines, with full year sales of EUR 7.9 billion [8] - The U.S. market share for influenza vaccines increased, particularly with Fluzone High-Dose and Flublok [8] - Beyfortus has protected over 11 million babies in more than 45 countries, preventing an estimated 200,000 hospitalizations [9] Company Strategy and Development Direction - The company is transitioning into an R&D-driven, AI-powered biopharma entity, focusing on business development and M&A opportunities [4] - Strategic acquisitions, including Vicebio and Dynavax Technologies, are aimed at enhancing the vaccine portfolio and expanding into older adult demographics [9][10] - The company plans to continue investing in manufacturing capacity to meet growing patient demand [14] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 to deliver profitable growth close to 2025 levels, with high single-digit sales growth anticipated [17][18] - The company is preparing for potential challenges in vaccine sales and is focused on maintaining a stable G&A expense structure [18] - Management highlighted the importance of innovation and collaboration in achieving sustainable healthcare goals [10] Other Important Information - The company completed a EUR 5 billion share buyback program and proposed a 5% increase in dividends for the 31st consecutive year [17] - Free cash flow returned to strong levels at EUR 8.1 billion, representing 18.5% of sales, with a target of reaching at least 20% in the medium term [15] Q&A Session Summary Question: Can you elaborate on the Dupixent rollout and its competition? - Management reported strong performance with 25% year-over-year growth for Dupixent, driven by new indications like CSU and COPD [30][31] Question: What is the growth outlook for Beyfortus in 2026? - Management expressed optimism about Beyfortus performance, noting its availability in over 45 countries and a positive real-world evidence publication [34][36] Question: What are the prospects for Amlitelimab and its market penetration? - Management remains confident in Amlitelimab's potential, emphasizing its novel mechanism and the importance of ongoing data collection [39][41] Question: How is the company addressing the recent changes in the U.S. pediatric vaccination schedule? - Management acknowledged potential confusion but emphasized proactive engagement with healthcare providers to maintain vaccination rates [77][78] Question: What is the strategy for capital allocation moving forward? - Management indicated a dynamic allocation strategy guided by AI, focusing on maximizing value from investments [60]

Core Viewpoint - Kimberly-Clark Corporation and Kenvue Inc. have received overwhelming shareholder approval for Kimberly-Clark's acquisition of Kenvue, marking a significant step towards creating a global health and wellness leader [1][2]. Group 1: Transaction Details - The acquisition transaction is expected to close in the second half of 2026, pending regulatory approvals and other customary closing conditions [3]. - Approximately 96% of shares present at Kimberly-Clark's Special Meeting voted in favor of the share issuance related to the transaction [2]. - At Kenvue's Special Meeting, about 99% of shares voted to adopt the merger agreement, representing approximately 77% of all outstanding shares [2]. Group 2: Company Statements - Kimberly-Clark's CEO, Mike Hsu, expressed gratitude to shareholders for their support and emphasized the potential to raise care standards for billions globally while generating significant shareholder value [2]. - Kenvue's CEO, Kirk Perry, highlighted the growth opportunities for the combined company and the potential to accelerate innovation and expand access to trusted brands [2]. Group 3: Company Backgrounds - Kimberly-Clark operates in over 175 countries with a portfolio of brands that hold No. 1 or No. 2 market share positions in approximately 70 countries, focusing on sustainable practices [4]. - Kenvue is recognized as the world's largest pure-play consumer health company by revenue, with a heritage of over a century and a portfolio of well-known brands [5].

Gentherm and Modine Performance Technologies Merger Conference Call Summary Company and Industry Overview - **Companies Involved**: Gentherm (NasdaqGS:THRM) and Modine Performance Technologies - **Industry**: Thermal management technologies, focusing on automotive, commercial vehicles, heavy-duty equipment, and power generation Key Points and Arguments Merger Announcement - Gentherm announced a definitive agreement to merge with Modine's Performance Technologies business, intended to be tax-free for Modine and its shareholders [2][20] - The merger is valued at approximately $1 billion, representing a multiple of about 6.8x based on pro forma synergy-adjusted EBITDA of $147 million for the trailing 12 months [20] Financial Impact - The merger will nearly double Gentherm's revenue to approximately $2.6 billion, with a pro forma synergy-adjusted EBITDA margin of about 13% [4][19] - Gentherm expects to achieve a mid-teens EBITDA margin through operational improvements and growth in higher-margin markets [19] Strategic Benefits - The merger expands Gentherm's portfolio with complementary thermal management products and engineering capabilities, enhancing access to growth markets outside of light vehicles [5][11] - Identified annual cost synergies of approximately $25 million by the end of 2028, with opportunities in direct materials, purchasing, logistics, and support costs [15][20] Market Expansion - The merger allows Gentherm to shift its revenue mix away from light vehicles, with light vehicle business expected to represent about 63% of combined revenue post-merger [36] - Commercial vehicles and heavy-duty applications will account for approximately 30%, while power generation is projected to be the fastest-growing segment at about 6% of the business [36] Growth Opportunities - Modine's established presence in the power generation market is expected to drive significant growth, with a long-term growth model suggesting over 20% growth for this segment [38] - Cross-selling opportunities identified, particularly in agriculture and mining equipment, leveraging Modine's existing customer relationships [52][41] Operational Excellence - Gentherm aims to learn from Modine's well-established operating system and 80/20 principles, which have led to significant financial and operational improvements [18][53] - The merger is seen as a chance to accelerate operational and commercial excellence, expanding margins and creating shareholder value [18] Additional Important Information - Gentherm shareholders will own approximately 60% of the combined company, while Modine shareholders will hold 40% [21] - The transaction is expected to close in the fourth quarter of 2026, subject to shareholder approval and customary closing conditions [22] - The combined company will continue to operate under the Gentherm name and will remain listed on NASDAQ [21] Conclusion - The merger between Gentherm and Modine Performance Technologies is positioned as a transformative opportunity that enhances scale, diversifies revenue streams, and creates significant growth potential across multiple markets, particularly in power generation and commercial vehicles [4][22]

Group 1 - Kirkland & Ellis was the top legal adviser for oil and gas sector mergers and acquisitions (M&A) in 2025, advising on 51 deals valued at $81.9 billion [1][3] - Latham & Watkins followed Kirkland & Ellis with advised deals worth $78.4 billion, while Simpson Thacher & Bartlett ranked third with $48.4 billion [2] - In terms of deal volume, Latham & Watkins secured the second position with 35 deals, followed by Vinson & Elkins with 30 deals [2] Group 2 - Kirkland & Ellis retained its leadership position in both deal value and volume from 2024 to 2025, although it experienced a drop in value terms despite an increase in the number of deals advised [3] - The data for the league tables is sourced from real-time tracking of company and advisory firm websites, ensuring comprehensive coverage of M&A activities [3][4]

LAZARD JANUARY 2026 Investor Presentation Safe Harbor This presentation contains certain statements, estimates and forecasts with respect to future performance and events. These statements, estimates and forecasts are "forward- looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "could," ...

Nomura took back the top spot in advising on Japanese mergers and acquisitions in 2025 when deals related to the country hit a record https://t.co/5NIYfaE1Pf ...

Today in Bloomberg Deals: A shift in approach to private equity transactions in China, ING predicts a wave of European banking M&A and bidding for a top Indian cricket team moves forward. https://t.co/37R5dueO4f ...

Morgan Stanley and RBC Capital Markets were the leading financial advisers for oil and gas sector mergers and acquisitions (M&A) in 2025, based on a league table from data analytics company GlobalData. According to GlobalData, Morgan Stanley achieved the top ranking by deal value, advising on transactions totalling $57.3bn. RBC Capital Markets distinguished itself in terms of volume, with advisory roles in 24 separate deals. Data from GlobalData's Financial Deals Database highlights that JPMorgan secure ...

Core Insights - New Gold Inc. shareholders overwhelmingly approved a plan of arrangement with Coeur Mining, with 99.22% voting in favor of the transaction [1] - The transaction involves Coeur Mining acquiring all outstanding common shares of New Gold, with shareholders receiving 0.4959 shares of Coeur for each New Gold share held [1] - The anticipated closing date for the transaction is in the first half of 2026, pending regulatory approvals and customary closing conditions [1] Shareholder Support - The voting results showed 476,065,996 votes for and 3,727,348 votes against the arrangement resolution among all shareholders [1] - Excluding certain minority security holders, the votes for the resolution were 475,775,946 for and 3,727,348 against, indicating strong support [1] Company Synergies - The merger is expected to create a new North American precious metals company, enhancing exploration potential and extending mine life [1] - The combined company will have approximately 62% of shares owned by Coeur shareholders and 38% by New Gold shareholders post-transaction [1] Regulatory and Closing Conditions - The transaction is subject to final approval from the Supreme Court of British Columbia and other regulatory approvals [1] - The completion of the transaction is contingent upon satisfying customary closing conditions typical for such mergers [1]